Oppenheimer & Co. Inc. lowered its position in Mylan (NASDAQ:MYL) by 10.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 75,095 shares of the company’s stock after selling 8,686 shares during the period. Oppenheimer & Co. Inc.’s holdings in Mylan were worth $3,177,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Pzena Investment Management LLC raised its position in shares of Mylan by 84.1% in the 3rd quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock worth $712,770,000 after acquiring an additional 10,381,697 shares in the last quarter. Greenlight Capital Inc. raised its position in shares of Mylan by 0.4% in the 3rd quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock worth $337,048,000 after acquiring an additional 42,600 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Mylan by 6.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 4,095,700 shares of the company’s stock worth $128,481,000 after acquiring an additional 232,762 shares in the last quarter. Orbimed Advisors LLC raised its position in shares of Mylan by 20.9% in the 3rd quarter. Orbimed Advisors LLC now owns 3,601,100 shares of the company’s stock worth $112,967,000 after acquiring an additional 621,900 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Mylan by 20.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,553,480 shares of the company’s stock worth $111,450,000 after acquiring an additional 612,513 shares in the last quarter. 75.56% of the stock is owned by hedge funds and other institutional investors.

Shares of Mylan (NASDAQ MYL) opened at $40.41 on Wednesday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.95 and a current ratio of 1.46. Mylan has a 52 week low of $29.39 and a 52 week high of $47.82. The company has a market capitalization of $21,779.31, a price-to-earnings ratio of 25.10, a price-to-earnings-growth ratio of 1.10 and a beta of 1.35.

In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total transaction of $3,375,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.69% of the company’s stock.

Several research analysts have recently issued reports on MYL shares. TheStreet raised Mylan from a “c” rating to a “b-” rating in a research report on Wednesday, January 17th. Guggenheim started coverage on Mylan in a research report on Tuesday, December 12th. They issued a “buy” rating and a $59.00 target price for the company. UBS Group set a $46.00 target price on Mylan and gave the stock a “buy” rating in a research report on Monday, December 4th. ValuEngine raised Mylan from a “hold” rating to a “buy” rating in a research report on Friday, December 1st. Finally, BidaskClub raised Mylan from a “hold” rating to a “buy” rating in a research report on Friday, October 27th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the stock. Mylan presently has an average rating of “Buy” and an average target price of $44.65.

TRADEMARK VIOLATION WARNING: This story was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://theolympiareport.com/2018/02/14/oppenheimer-co-inc-decreases-stake-in-mylan-myl.html.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.